Cannell & Spears LLC Sells 28,433 Shares of IQVIA Holdings Inc. $IQV

Cannell & Spears LLC trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 60.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,734 shares of the medical research company’s stock after selling 28,433 shares during the quarter. Cannell & Spears LLC’s holdings in IQVIA were worth $3,558,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in IQV. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. raised its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new position in IQVIA in the third quarter worth approximately $36,000. Root Financial Partners LLC acquired a new stake in IQVIA in the third quarter valued at approximately $43,000. Finally, Hantz Financial Services Inc. grew its stake in IQVIA by 92.0% in the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 115 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.1%

Shares of IQVIA stock opened at $164.78 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a fifty day simple moving average of $201.58 and a 200 day simple moving average of $206.93. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a market capitalization of $27.96 billion, a P/E ratio of 20.96, a price-to-earnings-growth ratio of 1.59 and a beta of 1.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same period in the previous year, the firm earned $3.12 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IQV shares. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Royal Bank Of Canada began coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Morgan Stanley set a $240.00 price objective on shares of IQVIA in a report on Wednesday, February 11th. Citigroup dropped their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $229.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.